West Pharmaceutical (WST) director Janet Haugen reports equity awards

Rhea-AI Filing Summary

West Pharmaceutical Services director reports equity awards and holdings. Director Janet Haugen reported beneficial ownership of 1,320.262 shares of West Pharmaceutical common stock, which includes 1,071 restricted stock units and related dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors.

She also acquired 46 phantom stock units on 12/31/2025, each linked to one share of common stock at a reference price of $275.14, increasing her total phantom stock units to 208.3. These phantom units are to be settled in shares of stock when she terminates service as a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAUGEN JANET BRUTSCHEA

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,320.262(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Unit	(2)	12/31/2025		A		46		(2)	(2)	Common Stock	46	$275.14	208.3	D

Explanation of Responses:

1. Reflects 1,071 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

2. Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.

	/s/ Louis Lalli, as an agent for Janet Haugen	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did West Pharmaceutical (WST) director Janet Haugen report?

Janet Haugen reported acquiring 46 phantom stock units on 12/31/2025, each tied to one share of West Pharmaceutical common stock, under the company’s director compensation arrangements.

How many West Pharmaceutical (WST) shares does Janet Haugen beneficially own?

Following the reported transactions, Janet Haugen beneficially owns 1,320.262 shares of West Pharmaceutical common stock, including restricted stock units and dividend equivalents.

What restricted stock units were reported for West Pharmaceutical (WST) director Janet Haugen?

The filing notes that 1,071 shares of restricted stock units and related dividend equivalents will vest in full on the date of the next annual shareholder meeting and will be distributable under the Deferred Compensation Plan for Outside Directors.

What are the terms of Janet Haugen’s phantom stock units in West Pharmaceutical (WST)?

Janet Haugen holds phantom stock units that are to be settled by delivery of West Pharmaceutical common stock upon her termination as a director. After acquiring 46 additional units on 12/31/2025, she beneficially owns 208.3 phantom stock units.

What is Janet Haugen’s relationship to West Pharmaceutical Services (WST)?

Janet Haugen is reported as a director of West Pharmaceutical Services, Inc. on this Form 4, with the form filed for one reporting person.